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This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
medicine 2017. Other selected articles can be found
online at http://ccforum.com/series/
annualupdate2017. Further information about the
Annual Update in Intensive Care and Emergency
Medicine is available from http://www.springer.com/
series/8901.circulation (ROSC) [5, 6]. Lidocaine and nifekalant areBackground
Out‐of‐hospital cardiac arrest (OHCA) affects approxi-
mately 300,000 people in the United States, 280,000
people in Europe and 110,000 people in Japan each year
[1–3]. Among all the presentations of cardiac arrest
(asystole, pulseless electrical activity [PEA], ventricular
fibrillation [VF], and pulseless ventricular tachycardia
[pVT]), VF and pVT are considered the most treatment
responsive, but the rate of survival to hospital discharge
after OHCA remains markedly low [1–3]. To overcome
this time‐sensitive and severe condition that has a low
survival rate, the “chain of survival” concept was first in-
troduced by Newman [4] in the 1980s as follows: (1)
early access to emergency medical care; (2) early cardio-
pulmonary resuscitation (CPR); (3) early defibrillation;
and (4) early advanced cardiac life support. Even after
three decades of accumulation of evidence, the 2015
International Liaison Committee on Resuscitation
(ILCOR) guidelines still recommend immediate defibril-
lation with CPR as the treatment of choice for VF/pVT* Correspondence: t-tagami@nms.ac.jp
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© 2017 Tagami et al.in OHCA patients and that antiarrhythmic drugs can be
used as advanced life support during cardiac arrest in
patients with refractory ventricular dysrhythmias [5, 6].
Refractory VF/pVT is generally defined as failure to ter-
minate VF/pVT with one to three stacked shocks [5].
Antiarrhythmic drugs that may be used include amio-
darone, lidocaine, and nifekalant ([5, 6]; Table 1). The
ILCOR guidelines recommend the use of amiodarone as
first‐choice treatment for adult patients with refractory
VF/pVT to improve the rate of return of spontaneous
recommended as alternatives to amiodarone in the treat-
ment of refractory VF/pVT in adult patients. However,
as mentioned in the knowledge gap section of the latest
resuscitation guidelines [5], existing evidence is not
enough to suggest that amiodarone is superior to lidocaine
and/or nifekalant in terms of the critical outcome of sur-
vival to discharge. In a trial involving OHCA patients with
VF/pVT, Dorian et al. [7] reported that the rate of survival
to admission was significantly higher in the amiodarone
group than in the lidocaine group but found no significant
difference in the rate of survival to discharge between the
two groups. More recently, Kudenchuk et al. [8] reported
survival data for patients with OHCA due to initial VF/
pVT in the prehospital setting and found that survival
rates with amiodarone or lidocaine administration were
not significantly higher than with placebo.
Thus, the provision of amiodarone, lidocaine, or nife-
kalant to OHCA patients with refractory VF/pVT is still
controversial in clinical practice. In this chapter, we
review the recent evidence from randomized trials and
observational studies for the efficacy of antiarrhythmic
drugs for OHCA patients with refractory VF/pVT.Characteristics and evidence of the efficacy of
antiarrhythmic drugs
Lidocaine was traditionally used as the drug of choice
for the treatment of OHCA in patients with persistent
Table 1 Classification and recommendations for the three antiarrhythmic drugs
Amiodarone Lidocaine Nifekalant
Vaughan Williams classification Class III Class Ib Class III
2015 ILCOR treatment
recommendation [5]
Suggest use of amiodarone in adult
patients with refractory VF/pVT to
improve rates of ROSC.
Suggest use of lidocaine as an
alternative to amiodarone in adult
patients with refractory VF/pVT.
Suggest use of nifekalant as an
alternative to amiodarone in adult
patients with refractory VF/pVT.






ILCOR International Liaison Committee on Resuscitation, VF ventricular fibrillation, pVT pulseless ventricular tachycardia
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a class Ib agent in the Vaughan‐Williams classification. Al-
though lidocaine is low‐cost and simple to administer, evi-
dence is not enough to suggest its superiority to other
antiarrhythmic drugs or placebo in terms of rate of survival
to hospital discharge of OHCA patients with persistent VF/
pVT. One retrospective study suggested that lidocaine may
improve the success rate of resuscitation [10], contrary to
the negative results reported in other studies [11, 12]. After
the reports of two landmark studies on amiodarone [7, 13],
resuscitation guidelines were revised with preference for
amiodarone over lidocaine in the treatment of cardiac ar-
rest patients with persistent VF/pVT [5, 6, 9].
Amiodarone and nifekalant are both classified as class
III antiarrhythmic agents (potassium channel blockers)
in the Vaughan‐Williams classification [14, 15]. However,
these two class III antiarrhythmic drugs have different
pharmacological characteristics. Amiodarone has several
effects on ion channels, receptors, and sympathetic ac-
tivity, in addition to blocking the rapid components of
delayed rectifier potassium currents, such as sodium and
calcium channel‐blocking effects, and α‐ and β‐receptor
blocking actions. In other words, amiodarone has nega-
tive inotropic and vasodilatory effects, which may nega-
tively affect hemodynamic status after ROSC in OHCA
patients. On the other hand, nifekalant is a pure potas-
sium channel blocker that specifically blocks the rapid
component of delayed rectifier potassium currents with-
out blocking sodium or calcium channels [16]. Labora-
tory studies suggest that nifekalant has no negative
inotropic effects and no effect on cardiac conduction
and hemodynamic status, whereas amiodarone has these
effects via its β‐blocking action [17, 18]. Although some
animal model studies suggested that amiodarone did not
contribute to the decrease in defibrillation threshold,
nifekalant was found to decrease the defibrillation
threshold of ventricular fibrillation [19–21]. Therefore,
nifekalant may have advantages over amiodarone for the
treatment of refractory VF/pVT via defibrillation and
post‐resuscitation hemodynamic management from a
pharmacological point of view. However, data from clin-
ical studies have provided limited robust results [22, 23].
Only a few studies have compared the efficacy of ami-
odarone with that of nifekalant for the treatment ofrefractory VF/pVT [22–25]. Amino et al. [22] reported
no significant differences in the success rate of defibrilla-
tion and rate of survival to discharge between nifekalant
and amiodarone in OHCA patients with refractory VF/
pVT. However, they reported that the interval between
antiarrhythmic drug administration and defibrillation
success in the amiodarone group was significantly longer
than that in the nifekalant group [22]. This finding was
also reported in a retrospective study by Harayama et al.
[23], who found that nifekalant achieved faster ROSC
after refractory VF/pVT than did amiodarone. More re-
cently, Amino et al. [25] evaluated the results of a large
multicenter prospective study (SOS‐KANTO 2012 [26]).
These investigators retrospectively investigated nifeka-
lant potency and differential effects of two initial amio-
darone doses (150 or 300 mg) as compared with
lidocaine doses in the Japanese population. The odds ra-
tios (ORs) for survival to admission were significantly
higher in the 150‐mg nifekalant or amiodarone group
than in the lidocaine group. The authors also reported
that 24‐hour survival was significantly higher in the nife-
kalant, 150‐mg amiodarone, or 300‐mg amiodarone
groups than in the lidocaine group. Amino et al. [27]
published another post hoc analysis from the SOS‐
KANTO 2012 study. They evaluated the effect of adminis-
tration of antiarrhythmic drugs (defined as any one among
or a combination of lidocaine, nifekalant, and amiodarone)
during CPR on 1‐month outcome by using propensity
score analyses. Logistic regression with propensity scoring
demonstrated an OR of 1.92 for 1‐month survival in the
antiarrhythmic drug group (p = 0.01) and 1.44 for favor-
able neurological outcome at 1 month (p = 0.26).
The ROC‐ALPS study
Recently, Resuscitation Outcomes Consortium (ROC)
investigators published the results of the Amiodarone,
Lidocaine or Placebo Study (ALPS), a randomized
double‐blind trial [8]. Amiodarone, lidocaine, or placebo
was administered by paramedics in the prehospital set-
ting for OHCA patients with refractory VF/pVT in 10
North American sites. The investigators evaluated 3,026
patients, of whom 974 were assigned to the amiodarone
group, 993 to the lidocaine group, and 1,059 to the pla-
cebo group. Of these patients, 24.4%, 23.7%, and 21.0%,
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come). The difference in survival rate was 3.2 percentage
points for amiodarone compared with placebo (95% confi-
dence interval [CI] −0.4 to 7.0; p = 0.08), 2.6 percentage
points for lidocaine compared with placebo (95% CI −1.0
to 6.3; p = 0.16), and 0.7 percentage points for amiodarone
compared with lidocaine (95% CI −3.2 to 4.7; p = 0.70).
The survival rates with favorable neurological status
(secondary outcome) were similar in the amiodarone group
(182 patients [18.8%]), lidocaine group (172 [17.5%]), and
placebo group (175 [16.6%]). The risk difference for the
secondary outcome was 2.2 percentage points for amioda-
rone compared with placebo (95% CI −1.1 to 5.6; p = 0.19),
0.9 percentage points for lidocaine compared with placebo
(95% CI −2.4 to 4.2; p = 0.59), and 1.3 percentage points
for amiodarone compared with lidocaine (95% CI −2.1 to
4.8; p = 0.44).
Kudenchuk et al. [8] concluded the ROC‐ALPS study
as follows: neither amiodarone nor lidocaine resulted in a
survival rate or favorable neurological outcome that was
significantly better than that achieved with placebo among
patients with OHCA due to initial shock‐refractory VF/
pVT. However, the study also provided insightful data to
the field of resuscitation. The authors reported that among
1,934 patients with bystander‐witnessed arrest, the sur-
vival rate was higher with amiodarone (27.7%) or lidocaine
administration (27.8%) than with placebo (22.7%). This
absolute risk difference was significant for amiodarone
compared with placebo (5.0 percentage points; 95% CI
0.3–9.7; p = 0.04) and for lidocaine compared with placebo
(5.2 percentage points; 95% CI 0.5–9.9, p = 0.03). The sur-
vival rate was also higher among amiodarone recipients
than among placebo recipients with emergency medical
services (EMS)‐witnessed arrest, with a risk difference of
21.9 percentage points (95% CI 5.8–38.0; p = 0.01). Con-
sidering that OHCA with refractory VF/pVT is a time‐
sensitive condition with a low survival rate, determining
whether OHCA was witnessed or not is a reasonable
method of performing subanalyses. The authors also re-
ported that among 839 patients with unwitnessed OHCA,
survival did not differ significantly between trial groups.
These data may indicate that both amiodarone and
lidocaine therapies may be effective for shock‐refractory
bystander‐witnessed OHCA but may be useless in unwit-
nessed OHCA.
Analyses of data from a Japanese nationwide
database: comparisons between amiodarone and
nifekalant and between amiodarone and
lidocaine
Nifekalant was developed and approved for clinical use
in Japan in 1999. Thus, nifekalant and lidocaine were the
traditionally used drugs of choice for VF/pVT until the
Japanese Ministry of Health, Labour and Welfareapproved the use of intravenous amiodarone in June
2007. Thus, Japan is the only country in which amioda-
rone, nifekalant, and lidocaine are all approved for
clinical use. We therefore decided to analyze the effective-
ness of antiarrhythmic drugs by using real‐world clinical
data from cardiogenic OHCA patients with refractory VF/
pVT on hospital arrival across the country.
We retrospectively evaluated data from the Japanese
Diagnosis Procedure Combination (DPC) database, which
is a nationwide in‐hospital patient administrative database
[28–30]. The DPC database includes administrative claims
and discharge abstract data for all patients (including
OHCA patients who die in the emergency room) dis-
charged from more than 1,000 participating hospitals,
covering all 82 academic hospitals and more than 90% of
all tertiary‐care emergency hospitals in Japan. The data-
base includes the following information for each patient,
recorded using a uniform data submission form: age,
sex, medical procedures (e. g., defibrillation, therapeutic
hypothermia, and percutaneous coronary angiogram/
intervention), daily records of all drugs administered and
devices used (e. g., amiodarone, nifekalant, lidocaine,
extracorporeal membrane oxygenation [ECMO], and
intra‐aortic balloon pumping [IABP]), length of hospital
stay, and discharge status (home, transfer to another
hospital, death in the emergency room, or death after ad-
mission) [28–30].
We compared the rates of survival to discharge among
cardiogenic OHCA patients with persistent VF/pVT on
hospital arrival following treatment with either amioda-
rone or nifekalant [28], and amiodarone or lidocaine [29].
In the study that compared amiodarone and nifekalant
[28], we identified 2,961 patients with cardiogenic
OHCA who had VF/pVT on hospital arrival between
July 2007 and March 2013. Patients were categorized into
amiodarone (n = 2,353) and nifekalant groups (n = 608),
from which 525 propensity score‐matched pairs were gen-
erated. We found a significant difference in admission rate
between the nifekalant and amiodarone groups in the pro-
pensity score‐matched groups (75.6 vs. 69.3%; difference
6.3%; 95% CI 0.9–11.7). An analysis that used the in‐hos-
pital administration rate of nifekalant/amiodarone as an
instrumental variable found that receiving nifekalant was
associated with an improved admission rate (22.2%; 95%
CI 11.9–32.4). However, we found no significant differ-
ence in in‐hospital mortality between the nifekalant and
amiodarone groups (81.5 vs. 82.1%; difference −0.6%; 95%
CI −5.2 to 4.1). Instrumental variable analysis showed that
receiving nifekalant was not associated with reduced
in‐hospital mortality (6.2%, 95% CI −2.4 to 14.8). We
concluded that although nifekalant may potentially
improve hospital admission rates compared with ami-
odarone for these patients, no significant association
with in‐hospital mortality was found between nifekalant
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pVT on hospital arrival.
In the study that compared amiodarone and lidocaine
[29], we identified 3,951 patients from 795 hospitals who
experienced cardiogenic OHCA and had refractory ven-
tricular fibrillation on hospital arrival. The patients were
categorized into amiodarone (n = 1,743) and lidocaine
(n = 2,208) groups, from which 801 propensity score‐
matched pairs were generated. No significant difference in
the rate of survival to hospital discharge was found be-
tween the amiodarone and lidocaine groups (15.2 vs.
17.1%; difference −1.9%; 95% CI −5.5 to 1.7) in the pro-
pensity score‐matched analyses. Thus, we concluded that
the amiodarone and lidocaine groups had no significant
difference in the rate of survival to hospital discharge.
As compared with those reported in the ROC‐ALPS
study, the survival rates of our two nationwide observa-
tional studies were lower (approximately 17–18% in our
studies [28, 29] vs. 24% in the ROC‐ALPS study [8]).
These differences may be attributed to the differences in
the EMS of the countries in which the studies were con-
ducted. The ROC‐ALPS study [8] was conducted in North
America, whereas we analyzed Japanese data. In the ROC‐
ALPS study [8], patients were randomized at the scene by
the responding paramedics. This is in contrast to our
study, in which antiarrhythmic drugs were provided after
hospital arrival because paramedics are not allowed to ad-
minister any antiarrhythmic drugs in prehospital settings
in Japan. Thus, the times from cardiac arrest to first ad-
ministration of the antiarrhythmic drug were much longer
in our studies [28, 29] than in the ROC‐ALPS study [8].
Recent systematic review and meta‐analyses
Huang et al. [31] reviewed 10 randomized controlled tri-
als and 7 observational trials in 2013. They found that
amiodarone (relative risk [RR] 0.82; 95% CI 0.54–1.24),
lidocaine (RR 2.26; 95% CI 0.93–5.52) and nifekalant
therapies did not improve survival to hospital discharge
compared with placebo, but amiodarone, lidocaine, and
nifekalant therapies were beneficial to initial resuscita-
tion, as assessed based on the rate of ROSC and survival
to hospital admission, with amiodarone being superior
to lidocaine (RR 1.28; 95% CI 0.57–2.86) and nifekalant
(RR 0.50; 95% CI 0.19–1.31).
Amino et al. reported a systematic review of the use of
intravenous amiodarone and nifekalant in 2014 [32].
They reviewed 9 articles, including those written in the
Japanese language. They found that amiodarone and
nifekalant therapies were equally effective in preventing
electrical storm (67 vs. 67%). The defibrillation effect on
CPR was also equal in the two groups (60 vs. 54%). More
cases of hypotension and bradycardia were recorded as
adverse effects in the amiodarone group (9.5 and 5.3%)
than in the nifekalant group [32].After publication of the results of the ROC‐ALPS
study, two systematic reviews with meta‐analyses were
published in 2016 [33, 34]. Laina et al. [34] reported that
amiodarone therapy significantly improved survival to
hospital admission (OR 1.402; 95% CI 1.068–1.840; Z =
2.43; p = 0.015), but neither survival to hospital discharge
(RR 0.850; 95% CI 0.631–1.144; Z = 1.07; p = 0.284) nor
neurological outcome (OR 1.114; 95% CI 0.923–1.345; Z =
1.12; p = 0.475) were significantly improved by amiodarone
therapy compared with placebo or nifekalant therapy. Sanfi-
lippo et al. [33] reported another review regarding this
issue. They reported that amiodarone was as beneficial as
lidocaine for survival to hospital admission (primary ana-
lysis OR 1.02; 95% CI 0.86–1.23; p = 0.40) and discharge
(primary analysis OR 1.06; 95% CI 0.87–1.30; p = 0.56;
secondary analysis OR 1.04; 95% CI 0.86–1.27; p = 0.67).
Compared with placebo, survival to hospital admission was
higher with both amiodarone (primary analysis OR 1.32;
95% CI 1.12–1.54; p < 0.0001; secondary analysis OR 1.25;
95% CI 1.07–1.45; p < 0.005) and lidocaine (secondary ana-
lysis only OR 1.34; 95% CI 1.14–1.58; p = 0.0005) therapies.
With regard to hospital discharge, no significant differences
were observed between placebo and amiodarone (primary
outcome OR 1.19; 95% CI 0.98–1.44; p = 0.08; secondary
outcome OR 1.11; 95% CI 0.92–1.33; p = 0.28) or lidocaine
(secondary outcome only OR 1.19; 95% CI 0.97–1.45;
p = 0.10) therapy.
These recent four systematic reviews with meta‐ana-
lyses suggested that amiodarone, lidocaine and nifekalant
therapies equally improved survival to hospital admis-
sion as compared with placebo. However, none of these
antiarrhythmic drugs improved long‐term outcomes.
Is earlier provision of antiarrhythmic drugs better?
After publication of the results of the ROC‐ALPS study,
several corresponding editorials and comments were
published in response [35–38]. As pointed out by several
comments, the key finding of the ROC‐ALPS study was
that both amiodarone and lidocaine therapies may be ef-
fective for shock‐refractory VF/pVT in bystander‐wit-
nessed arrest but might be useless in the later phase of
resuscitation [35, 37]. The first dose of the trial drugs
was given a mean (±SD) of 19.3 ± 7.4 min after the initial
call to EMS and after a median of three shocks in the
overall population of the ROC‐ALPS study [8].
Kudenchuk et al. speculated that such delays may at-
tenuate the effectiveness of antiarrhythmic interventions
as patients progress to the metabolic phase of OHCA
when cellular injury and physiological derangements
may be irreversible despite restored circulation [39]. The
potential benefit of treatment could have been underesti-
mated among patients with unwitnessed OHCA. Patients
with witnessed OHCA who received earlier initiation of
resuscitation and a shorter interval to antiarrhythmic drug
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survival to hospital discharge by about 5%.
Conclusion
Recent guidelines on resuscitation recommend immedi-
ate defibrillation with CPR as the treatment of choice for
OHCA patients with VF/pVT and that antiarrhythmic
drugs (including amiodarone, lidocaine and nifekalant) can
be used as advanced life support during cardiac arrest in
patients with refractory ventricular dysrhythmias. Recent
systematic reviews and meta‐analyses suggest that amioda-
rone, lidocaine, and nifekalant therapies equally improve
survival to hospital admission compared with placebo.
However, none of these antiarrhythmic drugs improved
long‐term outcomes. The landmark study, ROC‐ALPS,
concluded that compared with placebo, neither amioda-
rone nor lidocaine therapy resulted in a significantly higher
rate of survival or more favorable neurological outcome
among patients with OHCA due to refractory VF/pVT.
However, the authors also reported that among patients
with bystander‐witnessed cardiac arrest, the survival rate
was higher with amiodarone or lidocaine than with pla-
cebo. Although further studies are required to confirm this
speculation, earlier administration of antiarrhythmic drugs
may result in better outcomes.
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